Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Alvogen Inc.

www.alvogen.com

Latest From Alvogen Inc.

Market Brief: Sales Of Patches To Treat Neurological Disorders Will See Fastest Growth In Global Transdermal Patch Market

The overall transdermal patch market is expected to grow at a CAGR of 2.4% by 2024. Patches to treat neurological disorders will see the fastest growth while pain-management patches will see the most sales.

Market Intelligence Innovation

Beyond COVID-19: Ousted BARDA Chief’s Whistleblower Complaint Suggests Widespread Politicization of HHS Funding Decisions

Ousted BARDA Director Rick Bright's whistleblower complaint cites a long-pattern of political interference in scientific decisions making and could lead to overhauls in how BARDA and other HHS contracts are awarded to the drug industry. It could also impact how Congress funds BARDA, following a recent move by lawmakers to give the division more direct control of its funding. 

Coronavirus COVID-19 Politics

Deal Watch: Novartis Partners With TScan To Develop T-Cell Receptor-Targeted Therapies

Novartis/TScan and Gilead/Kite/oNKo-innate partnerships seek to advance cancer cell therapy. J&J, Bayer among the latest pharmas to unveil partnerships to fight the novel coronavirus.

Deals Business Strategies

Alvogen And Zentiva Complete CEE Deal

Alvogen’s central and eastern European business, which started up in 2010, has now been sold to the Zentiva group. Zentiva plans to combine both companies’ branded generics and OTC businesses in the CEE region.

Deals Strategy
See All

Company Information

  • Industry
  • Contract Research, Toxicology Testing-CRO
  • Pharmaceuticals
    • Drug Delivery
      • Controlled Release
      • Topical Delivery
      • Transdermal
    • Generic Drugs
    • Nutraceuticals
    • OTC, Consumer
  • Services
  • Therapeutic Areas
  • Cancer
  • Cardiovascular
  • Gastrointestinal
  • Neurology, Nervous System
  • Respiratory, Pulmonary
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Alvogen Inc.
  • Senior Management
  • Robert Wessman, Chmn. & CEO
    Joel Morales, CFO
    Thor Kristjansson, EVP, M&As
    Faysal Kalmoua, EVP, Portfolio
    Martina Feitzinger, EVP, Strategic Regulatory Affairs
  • Contact Info
  • Alvogen Inc.
    Phone: (973) 796-3400
    44 Whippany Rd.
    Ste. 300
    Morristown, NJ 07960
    USA
UsernamePublicRestriction

Register